Transgene appoints Nathalie Adda as chief medical officer
September 21, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Nathalie Adda, Transgene
Transgene has announced the appointment of Dr Nathalie Adda as chief medical officer. Responsible for medical and regulatory affairs of …
Merz Pharma slammed by PMCPA
September 21, 2012Medical Communications, Sales and Marketing ABPI, Merz Pharma, PMCPA
Merz Pharma UK has been rapped over the knuckles for three of the most serious breaches it is possible to …
Almirall’s COPD drug launched in Europe
September 20, 2012Sales and Marketing Advair, Almirall, Eklira, Genuair, Seretide, Spiriva
Almirall has launched COPD treatment Eklira in Denmark following approval from the European Commission. Phase III trials demonstrated that Eklira …
Teva announces appointment of Prof Itzhak Krinsky
September 20, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Itzhak Krinsky, Teva
Teva has announced the appointment of Professor Itzhak Krinsky as chairman of Teva Japan and Teva South Korea and head …
Sanofi cleared in sales row
September 20, 2012Medical Communications, Sales and Marketing ABPI, CDF, Jevtana, PMCPA, Sanofi
Sanofi has been cleared of any wrongdoing after allegations that it had broken multiple clauses in the ABPI Code of …
Boehringer submits new lung cancer drug
September 20, 2012Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib
Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …
Sandra Peterson joins J&J’s executive committee
September 20, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Sandra Peterson
Sandra Peterson will join Johnson & Johnson on 1 December as Group Worldwide chairman and member of the company’s executive …
Afinitor’s new UK indication launched
September 20, 2012Sales and Marketing Afinitor, CHMP, Novartis, breast cancer
Novartis’ cancer drug Afinitor has been made available in the UK for patients with the most common form of advanced …
RSA announces new Board members
September 20, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Nick Stephens, RSA executive search
Life sciences executive search and interim management specialists RSA has announced the appointment of Nick Stephens as executive chairman, John …
Silence Therapeutics appoints chief medical adviser
September 19, 2012Business Services, Research and Development, Sales and Marketing Michael Khan, Silence Therapeutics
Silence Therapeutics has announced the appointment of Michael Khan to its board of directors as chief medical adviser. Dr Khan …
J&J sets up life science centres
September 19, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, R&D, innovation
Johnson & Johnson is to set up what it calls regional innovation centres in a bid to speed up the …
Steven Gillis to join Shire Board of directors
September 19, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, Steven Gillis
Shire has announced that Dr Steven Gillis will join the Board of directors in October this year. On joining the …
Salmonson is new chair of CHMP
September 19, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CHMP, EMA, MPA, Salmonson
Dr Tomas Salmonson has been elected chair of the Committee for Medicinal Products for Human Use (CHMP) for a three-year …
Circassia appoints Stewart Sharpe as VP Commercial Operations
September 19, 2012Medical Communications, Research and Development, Sales and Marketing Circassia, Stewart Sharpe
Speciality biopharma firm Circassia has announced the appointment of Stewart Sharpe to the newly-created position of vice president, Commercial Operations. …
Two new appointments at Pharmalink Consulting
September 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kevin Webb, Lorcan Flanagan, Pharmalink
Regulatory affairs specialists Pharmalink Consulting has announced two new appointments. Lorcan Flanagan (pictured) joins as European Business Development manager and …
Boehringer says it is rolling out ‘fully disposable’ biomanufacturing
September 18, 2012Manufacturing and Production Boehringer, CMO, GMP, SUSs
Boehringer Ingelheim says it has developed a production platform for biopharmaceuticals that makes full use disposable technologies both upstream and …
API supply issues lead Lundbeck to drop cancer drug
September 18, 2012Manufacturing and Production Elspar, Lundbeck, Ovation
Danish firm Lundbeck has decided to discontinue supplies of its leukaemia drug Elspar from December after struggling to find a …
UK at centre of Eisai plans
September 18, 2012Research and Development, Sales and Marketing CNS, Cancer Drugs Fund, Eisai, Fycompa, Halaven
Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as …
Pfizer issues guide for medicines disposal
September 18, 2012Manufacturing and Production EPA, PRDA, Pfizer
Pfizer has published a guide for the safe disposal of medicines targeted at healthcare professionals and facilities in the US. …
Asia-Pacific – pharma’s new centre of gravity?
September 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Asia-Pacific, AstraZeneca
A high-growth region for the pharmaceutical industry, Asia-Pacific incorporates a vast geography with a $20 trillion economy, and is home …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
